Question follow-through · 15321

Innovation and Technology: Obesity

To ask the Secretary of State for Science, Innovation and Technology, what funding has been allocated within the Obesity Pathway Innovation Programme to assess the outcomes of that programme.

answeredDepartment for Science, Innovation and Technology

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department for Science, Innovation and Technology
Tabled
2 Jul 2026
Target answer date
6 Jul 2026
Answer
13 Jul 2026 · 11 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Recorded timeline

  1. 2 Jul 2026

    Question tabled

    To ask the Secretary of State for Science, Innovation and Technology, what funding has been allocated within the Obesity Pathway Innovation Programme to assess the outcomes of that programme.

  2. 6 Jul 2026

    Target answer date

    Date supplied by the official written-questions record.

  3. 13 Jul 2026

    Answer published

    The Obesity Pathway Innovation Programme includes evaluation activity to assess programme outcomes, funded from within the programme's budget. The programme's 12 funded projects will generate real-world evidence on innovative approaches to obesity care, s...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Strong linkSame MP, department and exact heading

Innovation and Technology: Obesity

14 Jul 2026 · To ask the Secretary of State for Science, Innovation and Technology, pursuant to the Answer of 13 July 2026 to Question 15321 on Innovation and Technology: Obesity, whether the evaluation activity will be independent of Eli Lilly and Company; whether it